Applied Therapeutics (NASDAQ:APLT) Stock Rating Lowered by BidaskClub

Applied Therapeutics (NASDAQ:APLT) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Saturday, BidAskClub reports.

APLT has been the subject of a number of other research reports. Cowen reissued a “buy” rating on shares of Applied Therapeutics in a report on Wednesday, January 8th. Citigroup upped their price target on shares of Applied Therapeutics from $29.00 to $44.00 and gave the stock a “buy” rating in a report on Thursday, January 9th. UBS Group upped their price target on shares of Applied Therapeutics to and gave the stock a “buy” rating in a report on Monday, January 27th. Robert W. Baird upped their price target on shares of Applied Therapeutics from $24.00 to $43.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. Finally, Zacks Investment Research raised shares of Applied Therapeutics from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a report on Tuesday, January 14th. Six analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $49.75.

NASDAQ APLT opened at $45.76 on Friday. Applied Therapeutics has a 12-month low of $7.95 and a 12-month high of $57.39. The firm has a 50-day moving average price of $43.84 and a two-hundred day moving average price of $21.23.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.14). On average, research analysts forecast that Applied Therapeutics will post -3.07 EPS for the current fiscal year.

In other news, Director Stacy J. Kanter purchased 6,500 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was bought at an average price of $49.60 per share, with a total value of $322,400.00. Following the acquisition, the director now owns 6,500 shares in the company, valued at approximately $322,400. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Several institutional investors have recently modified their holdings of APLT. California State Teachers Retirement System bought a new stake in shares of Applied Therapeutics during the 3rd quarter worth approximately $35,000. Citigroup Inc. increased its position in Applied Therapeutics by 1,385.4% during the 4th quarter. Citigroup Inc. now owns 1,322 shares of the company’s stock worth $36,000 after purchasing an additional 1,233 shares in the last quarter. Northern Trust Corp acquired a new position in Applied Therapeutics during the 2nd quarter worth approximately $59,000. Bank of America Corp DE increased its position in Applied Therapeutics by 171.9% during the 4th quarter. Bank of America Corp DE now owns 2,518 shares of the company’s stock worth $69,000 after purchasing an additional 1,592 shares in the last quarter. Finally, American International Group Inc. increased its position in Applied Therapeutics by 214.7% during the 4th quarter. American International Group Inc. now owns 4,009 shares of the company’s stock worth $109,000 after purchasing an additional 2,735 shares in the last quarter. 12.96% of the stock is owned by institutional investors.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.

Read More: Stock Portfolio Tracker

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.